Biotech Led by 29-Year-Old CEO Now Worth Billions With No Sales

What's Behind the Soaring Pay for Biotech Executives?

Investors are giving Axovant Sciences Ltd. an almost $3 billion valuation after its public-market debut. Not bad for a company that is years away from making a dime of sales, if it ever does.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.